Enzymatic Therapy improves its product quality with Russell Finex screening technology

Published: 24-Apr-2019

When Enzymatic Therapy stopped outsourcing and built its own FDA-approved manufacturing facility, the goal was to improve product quality, streamline production, and ramp up sales growth. A crucial step was selecting the right sieving equipment to remove any agglomerates, oversize particles or contaminants from incoming raw dry materials.

For quality assurance and maintenance reasons, the company frowned on brushes or metal rollers that pushed product through the sieve as this could result in contamination such as brush fibres. To resolve these challenges, Enzymatic Therapy chose a high-capacity, 22-inch Russell Compact Sieve from Russell Finex.

The first step in ensuring quality involves passing all dry materials through a 16-mesh screen to remove oversize particles. A special magnetic trap removes any submesh sized ferrous contaminants, which can sometimes occur due to the pulverizing or processing of raw materials into powder. Some materials are also run through a finer 40-mesh screen to improve binding with other materials. 

The unique vibratory screeners are a breakthrough improvement over conventional screeners where reliability, cleaning efficiency, and headroom or room size are issues. Since the Russell Compact Sieve is crevice-free - and entirely constructed from polished stainless steel including stands - all surfaces are easily cleanable. Its simple design makes it easy to strip down and clean without tools.

Russell Finex has provided sanitary separation solutions to the pharmaceutical industry for 85 years. Contact Russell Finex directly to speak with an expert sales engineer and discuss requirements.

You may also like